CAMBRIDGE, Mass., Sept. 25, 2018 /PRNewswire/ -- Leap
Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today
announced that Christopher K.
Mirabelli, Ph.D., Chairman, President and Chief Executive
Officer, will present a corporate overview at the following
investor conferences:
- The Ladenburg Thalmann 2018 Healthcare Conference in
New York City on Tuesday, October 2, 2018 at 11:00 a.m. ET.
- The Cantor Fitzgerald 2018 Global Healthcare Conference in
New York City on Wednesday, October 3, 2018 at 8:00 a.m. ET.
These presentations will be webcast live and may be accessed on
the Investors page of the company's website at
www.investors.leaptx.com, where a replay of the event will also be
available for a limited time.
About Leap Therapeutics
Leap Therapeutics
(NASDAQ:LPTX) is focused on developing targeted and immuno-oncology
therapeutics. Leap's most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01
is in clinical trials in patients with esophagogastric cancer,
biliary tract cancer, and gynecologic cancers, with an emerging
focus on patients with defined mutations of the Wnt pathway and in
combination with immune checkpoint inhibitors. Leap's second
clinical candidate, TRX518, is a humanized GITR agonist monoclonal
antibody designed to enhance the immune system's anti-tumor
response that is in two advanced solid tumor studies. For more
information about Leap Therapeutics, visit http://www.leaptx.com or
our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements relating to
Leap's expectations with respect to the development and advancement
of DKN-01, TRX518, and other programs, including the initiation,
timing and design of future studies, enrollment in future studies,
business development, and other future expectations, plans and
prospects. Detailed information regarding factors that may cause
actual results to differ materially will be included in Leap
Therapeutics' periodic filings with the Securities and
Exchange Commission (the "SEC"), including Leap Therapeutics'
Form 10-K that Leap filed with the SEC on February 23, 2018. Any forward looking
statements contained in this release speak only as of its date. We
undertake no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Heather Savelle or Mary Jenkins
212-600-1902
heather@argotpartners.com
mary@argopartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-two-october-conferences-300717862.html
SOURCE Leap Therapeutics, Inc.